CD274 and neoplasm: Furthermore, when combining PD‐L1 CPS and serological tumor biomarkers with these two sRNAs, the AUCs were 0.89 (95% CI; 0.79–1.00) and 0.83 (95% CI; 0.70–0.96) for the discovery and validation cohorts, respectively.